16
May
2019

Amgen Swings for the RAS Fence, Gilead’s Grilling on Price, & Agios Enlarges the Pie

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Avidity Advances in FSHD, Insmed Passes PAH Test, Merck Delivers with Oral PCSK9
Sanofi Buys Blueprint, BMS Antes for BioNTech Bispecific, & Kymera Degrader Delivers
GSK Antibiotic Hits, ORIC Prostate Cancer Drug Shines, & Taysha Goes 10-for-10
Vigil, Inozyme Acquired, Prime Cuts, & Regeneron Scoops Up 23andMe